{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001314","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.562529+00:00","generated_at":"2026-05-28T06:27:41.084579+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cocrystal Pharma reports favorable Phase 1 safety/tolerability for oral antiviral CDI-988 at 800 mg for 10 days","bullets":["Phase 1 MAD study shows CDI-988 well-tolerated up to 800 mg/day for 10 days; new cohort at 1,200 mg for 5 days planned.","Pan-viral inhibitor targets norovirus and coronaviruses; no approved antivirals for norovirus exist.","Company plans to start human challenge study in norovirus-infected subjects later in 2025.","Norovirus outbreaks surge in U.S.; CDC estimates 21 million annual U.S. cases and $10.6B economic burden."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001314","json":"https://secwatch.observer/filing/0001493152-25-001314.json","markdown":"https://secwatch.observer/filing/0001493152-25-001314.md","text":"https://secwatch.observer/filing/0001493152-25-001314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225001314/0001493152-25-001314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225001314/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:27:41.084579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}